OGN
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy, and anesthesia. Organon sells to international markets.
Organon & Co. (OGN) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Growth (C-). The rating has held at C+ for 10 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B (3.2) | C- (1.9) | B- (3.0) | B (3.2) | C+ (2.6) | C+ (2.8) |
| 2026-11-06 | B (3.2) | C- (1.9) | B- (3.0) | B (3.2) | C+ (2.7) | C+ (2.8) |
| 2026-10-30 | B (3.2) | D+ (1.7) | B- (3.0) | B- (3.0) | C+ (2.7) | C+ (2.7) |
| 2026-10-23 | B (3.2) | D+ (1.7) | B- (3.0) | B+ (3.5) | C+ (2.6) | C+ (2.8) |
| 2026-10-16 | B (3.2) | D+ (1.8) | B- (3.0) | B (3.4) | C+ (2.6) | C+ (2.8) |